Packer M, Lee W H, Kessler P D, Medina N, Yushak M, Gottlieb S S
Department of Medicine, Mount Sinai School of Medicine of The City University of New York, New York.
J Am Coll Cardiol. 1987 Oct;10(4):837-44. doi: 10.1016/s0735-1097(87)80278-4.
To identify patients with severe chronic heart failure who are at greatest risk of developing functional renal insufficiency during converting enzyme inhibition, creatinine clearance was measured in 59 patients before and after long-term therapy with captopril (39 patients) or enalapril (20 patients), while digitalis and diuretic therapy was kept constant. Creatinine clearance increased or remained constant in 33 of the 59 patients (Group I), but declined in the remaining 26 patients (Group II). The two groups were similar with respect to the cause of heart failure, pretreatment renal function and all pretreatment hemodynamic variables. Patients in Group II, however, had lower values for serum sodium concentration (134.8 +/- 1.0 versus 137.0 +/- 0.6 mmol/liter) and higher values for plasma renin activity (10.6 +/- 3.4 versus 3.0 +/- 0.5 ng/ml per hour), received larger doses of furosemide (108 +/- 11 versus 84 +/- 6 mg/day), were more frequently diabetic (42 versus 15%) and were more frequently treated with enalapril (50 versus 21%) than were patients in Group I (all p less than 0.05). By stepwise logistic analysis, only hyponatremia (or an elevated plasma renin activity) and enalapril therapy independently predicted the decline in creatinine clearance during converting enzyme inhibition. These observations could not be explained by changes in systemic blood pressure. In patients with a normal serum sodium concentration (greater than or equal to 137 mmol/liter), creatinine clearance increased with captopril (+21%, p less than 0.05), but not with enalapril (-6%, p = NS).(ABSTRACT TRUNCATED AT 250 WORDS)
为了确定在使用转换酶抑制剂期间发生功能性肾功能不全风险最高的重度慢性心力衰竭患者,在59例患者长期接受卡托普利(39例患者)或依那普利(20例患者)治疗前后测量了肌酐清除率,同时洋地黄和利尿剂治疗保持不变。59例患者中有33例(第一组)肌酐清除率升高或保持不变,但其余26例患者(第二组)肌酐清除率下降。两组在心力衰竭病因、治疗前肾功能和所有治疗前血流动力学变量方面相似。然而,第二组患者的血清钠浓度较低(134.8±1.0对137.0±0.6 mmol/升),血浆肾素活性较高(10.6±3.4对3.0±0.5 ng/ml每小时),接受较大剂量的呋塞米(108±11对84±6 mg/天),糖尿病患者更常见(42%对15%),接受依那普利治疗的频率更高(50%对21%),均优于第一组患者(所有p均小于0.05)。通过逐步逻辑分析,只有低钠血症(或血浆肾素活性升高)和依那普利治疗可独立预测转换酶抑制期间肌酐清除率的下降。这些观察结果无法用全身血压的变化来解释。在血清钠浓度正常(大于或等于137 mmol/升)的患者中,卡托普利使肌酐清除率升高(+21%,p小于0.05),但依那普利则不然(-6%,p=无显著性差异)。(摘要截短于250字)